Chronic Hepatitis C Infection
56
0
0
45
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
28 trials with published results (50%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
10.7%
6 terminated out of 56 trials
88.2%
+1.7% vs benchmark
32%
18 trials in Phase 3/4
62%
28 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (56)
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC)
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
Therapeutic Hepatitis C Virus Vaccine
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
A Study to Evaluate Chronic Hepatitis C Infection
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients